Dr J�rg T�ubel, will be presenting again at the DIA 3rd Cardiac Safety Workshop in Japan, taking place in Tokyo from 28-29 May 2012.The 3rd Cardiac Safety Workshop in Japan will explore topics surrounding the future of the TQT study, including the emerging intensive QT studies, the use of positive controls for assay sensitivity, the risks involved in TQT studies, as well as other issues specific to Japan. The meeting will bring together experts and members of academia, regulatory and drug development organisations for 2 days of intensive discussion, debates and updates.Dr Taubel's extensive experience in investigating ethnic differences and bridging ECG studies exploring physiological and drug induced effects makes him a world leading expert in the evaluation of effects of ethnicity on the ECG. His recent work includes studies in both Caucasian and Japanese participants using techniques such as an euglycaemic insulin clamp investigating the effects of food on the QT interval in a proper ICH E14 setting. He will present some of his latest data.Click here to view the full programWe invite you to be a part of this hugely informative event on current issues facing the industry and network with like-minded scientific professionals. A Business Development representative from Richmond Pharmacology will also be standing by for the duration of the workshop to discuss your prospective TQT study requirements and how we can benefit towards its total success.To arrange a face to face meeting or request a copy of our latest TQT publication,contact a member of our BD Team today.

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event